The deVeber Institute for Bioethics and Social Research conducts and disseminates research on topics connected to human life in its biological, social and ethical dimensions. These topics are selected for study depending on emerging medical, technological and social developments. In undertaking this work the Institute believes that a sense of the inherent value and dignity of human life and of the human person as an end and not a means is a foundational perspective to bring to bear on its work.

The Institute's research may be original or may consist of reviews of existing literature. In each case the Institute's work is to be of the highest academic quality, though accessible to the general public.

From the Director's Desk

Abortion & Preterm Birth in the National Post

The deVeber Institute commends Barbara Kay for highlighting the abortion issue that we shouldn't be ignoring in this week's National Post article: 

The Abortion Issue We're Ignoring

Increasing amounts of research, which the deVeber Institute is documenting, is dispelling any doubt that a previous induced abortion increases a woman's risk of having a preterm birth in a subsequent pregnancy.

Hijacking Healing: Pro abortion response to post abortion stress

Ring Cassidy, E.  2003.  Life and Learning.

Death with Dignity or Obscenity?

Click on the attachment to see a two part article written by the pioneering palliative care nurse and deVeber Institute Advisor, Jean Echlin.

Part 1:  A Real Danger
Part 2:  Real Hope for the Dying

Originally published October 28th, 2008.

Don't spread false hope about stem cell research

Paul Ranalli, in the National Post, Tuesday April 21, 2009, wrote:

The hype generated around embryonic stem cells continues to grow out of control, judging by the National Post's front-page placement of the announcement of new British research study on age-related macular degeneration (AMD). Perhaps to counter the ethical darkness in using cells from aborted fetuses, the fawning publicity supporting embryonic stem cells has always far exceeded the reality.

In fact, there are exactly zero successful human treatments using embryonic cells. Despite the "huge step forward" headline, this news item is no exception. It merely announces that the multinational drug giant Pfizer has agreed to finance research trials which might lead to a human application "within seven years." Normally this would be covered in a one-paragraph item tucked back in the first section. Instead, the above-the-fold splash is sure to excite thousands of Canadian patients who might reasonably conclude that the Post would not make such a placement unless real patients had achieved real success. While one does not wish to dim anyone's hope, especially in this age of Obama, it must be tempered by reality. There are many, many hoops to go through, not least of which is the great difficulty in translating animal research on vision to a human therapy, especially one involving so delicate and precise a function as central vision.

Barbara Farlow in the CMAJ

Barbara Farlow, Advisor to the deVeber Institute, is featured in the Canadian Medical Association Journal (CMAJ) article:

Prenatal DNA test raises both hopes and worries

"I feel that the genetic testing ultimately determined her fate," says Farlow, who lives in Mississauga, Ontario. "She was treated as a syndrome. She wasn't treated as a child."

Read the complete article